{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T02:40:09Z","timestamp":1762483209251,"version":"build-2065373602"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,6]]},"DOI":"10.7759\/cureus.96256","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T02:35:51Z","timestamp":1762482951000},"source":"Crossref","is-referenced-by-count":0,"title":["Calcitriol as a Therapeutic Strategy for Ferric Carboxymaltose\u2013Induced Hypophosphatemia"],"prefix":"10.7759","author":[{"given":"Freny","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prince","family":"Modi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bosky","family":"Modi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rangesh","family":"Modi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Management of iron deficiency anemia","volume":"11","author":"Jimenez K","year":"2015","unstructured":"Jimenez K, Kulnigg-Dabsch S, Gasche C. Management of iron deficiency anemia. Gastroenterol Hepatol (N Y). 2015, 11:241-50.","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14643","article-title":"Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside-a systematic review and meta-analysis","volume":"87","author":"Schaefer B","year":"2021","unstructured":"Schaefer B, Tobiasch M, Viveiros A, Tilg H, Kennedy NA, Wolf M, Zoller H. Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside-a systematic review and meta-analysis. Br J Clin Pharmacol. 2021, 87:2256-73. 10.1111\/bcp.14643","journal-title":"Br J Clin Pharmacol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2450\/2014.0094-14","article-title":"Safety of intravenous iron formulations: facts and folklore","volume":"12","author":"Auerbach M","year":"2014","unstructured":"Auerbach M, Macdougall IC. Safety of intravenous iron formulations: facts and folklore. Blood Transfus. 2014, 12:296-300. 10.2450\/2014.0094-14","journal-title":"Blood Transfus"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-327897","article-title":"Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial","volume":"72","author":"Zoller H","year":"2023","unstructured":"Zoller H, Wolf M, Blumenstein I, et al.. Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial. Gut. 2023, 72:644-53. 10.1136\/gutjnl-2022-327897","journal-title":"Gut"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27220","article-title":"Expert consensus guidelines: intravenous iron uses, formulations, administration, and management of reactions","volume":"99","author":"Van Doren L","year":"2024","unstructured":"Van Doren L, Steinheiser M, Boykin K, Taylor KJ, Menendez M, Auerbach M. Expert consensus guidelines: intravenous iron uses, formulations, administration, and management of reactions. Am J Hematol. 2024, 99:1338-48. 10.1002\/ajh.27220","journal-title":"Am J Hematol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.73967","article-title":"Recurrent hypophosphatemia following a single dose of parenteral iron administration","volume":"16","author":"Kinnera S","year":"2024","unstructured":"Kinnera S, Owasoyo O, Rahim HM, et al.. Recurrent hypophosphatemia following a single dose of parenteral iron administration. Cureus. 2024, 16:e73967. 10.7759\/cureus.73967","journal-title":"Cureus"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2016-219160","article-title":"Severe hypophosphataemia after intravenous iron administration","volume":"2017","author":"Anand G","year":"2017","unstructured":"Anand G, Schmid C. Severe hypophosphataemia after intravenous iron administration. BMJ Case Rep. 2017, 2017:10.1136\/bcr-2016-219160","journal-title":"BMJ Case Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/411328-calcitriol-as-a-therapeutic-strategy-for-ferric-carboxymaltose-induced-hypophosphatemia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T02:35:53Z","timestamp":1762482953000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/411328-calcitriol-as-a-therapeutic-strategy-for-ferric-carboxymaltose-induced-hypophosphatemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":7,"URL":"https:\/\/doi.org\/10.7759\/cureus.96256","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,6]]}}}